Sensitivity to dabrafenib and trametinib treatments in patients with non-small-cell cancer harboring BRAF compound mutations: A pooled analysis of BRAF p.V600E-positive advanced non-small-cell lung cancer-Reference-Cited by-同舟云学术

Sensitivity to dabrafenib and trametinib treatments in patients with non-small-cell cancer harboring BRAF compound mutations: A pooled analysis of BRAF p.V600E-positive advanced non-small-cell lung cancer

Published:2022-08 Issue: Volume:266-267 Page:1-6
ISSN:2210-7762
Container-title:Cancer Genetics
language:en
Short-container-title:Cancer Genetics

Author:

Seto Katsutoshi,Shimizu Junichi^ORCID,Masago Katsuhiro^ORCID,Araki Mitsugu,Katayama Ryohei,Sagae Yukari,Fujita Shiro^ORCID,Horio Yoshitsugu^ORCID,Sasaki Eiichi^ORCID,Kuroda Hiroaki,Okubo Kenichi,Okuno Yasushi,Hida Toyoaki

Publisher

Elsevier BV

Subject

Cancer Research,Genetics,Molecular Biology

Reference19 articles.

1. A BRAF new world;Frisone;Crit Rev Oncol Hematol,2020

2. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial;Planchard;Lancet Oncol,2016

3. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial;Planchard;Lancet Oncol,2017

4. Negative reactions of BRAF mutation-specific immunohistochemistry to non-V600E mutations of BRAF;Seto;Pathol Int,2020

5. Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers;Peng;Cancer Cell,2015

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COMPARATIVE ANALYSIS OF MICROMETASTASIS INDICATORS AND PROGNOSIS IN FITNESS AND ATHLETIC PATIENTS WITH NON-SMALL CELL LUNG CANCER POST PULMONARY LOBECTOMY VERSUS SEGMENTECTOMY;REV INT MED CIENC AC;2023

2. Phytochemicals from Allium tuberosum Rottler ex Spreng Show Potent Inhibitory Activity against B-Raf, EGFR, K-Ras, and PI3K of Non-Small Cell Lung Cancer Targets;Applied Sciences;2022-11-18